TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06714864: Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age

Sponsor: CorMedix Therapeutics · Phase: PHASE4 · Area: INFECTIOUS_VACCINE · Target Enrollment: 36 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$776,160

Rescue Site Savings

+$517,440

Unlock Full NCT06714864 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06714864 Rescue Dossier →